On February 23, the U.S. Food and Drug Administration (FDA) approved Farydak (panobinostat) for the treatment of patients with multiple myeloma. Read more.
FDA approves Farydak for treatment of multiple myeloma
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.